{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:05:18Z","timestamp":1774469118224,"version":"3.50.1"},"reference-count":37,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2015,4,1]]},"DOI":"10.1136\/thoraxjnl-2014-206345","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T03:12:07Z","timestamp":1423797127000},"page":"311-319","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study"],"prefix":"10.1136","volume":"70","author":[{"given":"R.","family":"Buhl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Schuermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hiltl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Korn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,2,12]]},"reference":[{"key":"key-10.1136\/thoraxjnl-2014-206345-1","volume-title":"Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care","author":"National Clinical Guideline Centre","year":"2010"},{"key":"key-10.1136\/thoraxjnl-2014-206345-2","unstructured":"GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2014. http:\/\/www.goldcopd.com\/"},{"key":"key-10.1136\/thoraxjnl-2014-206345-3","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1183\/09031936.00200212","article-title":"Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study","volume":"42","author":"Bateman","year":"2013","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2014-206345-4","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","article-title":"Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD","volume":"107","author":"Donohue","year":"2013","journal-title":"Respir Med"},{"key":"key-10.1136\/thoraxjnl-2014-206345-5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.rmed.2010.09.006","article-title":"Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs","volume":"105","author":"Toy","year":"2011","journal-title":"Respir Med"},{"key":"key-10.1136\/thoraxjnl-2014-206345-6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1183\/09031936.05.00140404","article-title":"Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD","volume":"26","author":"van Noord","year":"2005","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2014-206345-7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.rmed.2010.02.017","article-title":"Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms","volume":"104","author":"van Noord","year":"2010","journal-title":"Respir Med"},{"key":"key-10.1136\/thoraxjnl-2014-206345-8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(12)70052-8","article-title":"Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study","volume":"1","author":"Vogelmeier","year":"2013","journal-title":"Lancet Respir Med"},{"key":"key-10.1136\/thoraxjnl-2014-206345-9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2165\/11208490-000000000-00000","article-title":"Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease","volume":"72","author":"McKeage","year":"2012","journal-title":"Drugs"},{"key":"key-10.1136\/thoraxjnl-2014-206345-10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2147\/COPD.S36001","article-title":"Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD","volume":"7","author":"Buhl","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"key-10.1136\/thoraxjnl-2014-206345-11","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.rmed.2013.05.016","article-title":"Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study","volume":"107","author":"Dahl","year":"2013","journal-title":"Respir Med"},{"key":"key-10.1136\/thoraxjnl-2014-206345-12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"key":"key-10.1136\/thoraxjnl-2014-206345-13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","article-title":"The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"key-10.1136\/thoraxjnl-2014-206345-14","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.rmed.2008.07.020","article-title":"Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study","volume":"102","author":"Vogelmeier","year":"2008","journal-title":"Respir Med"},{"key":"key-10.1136\/thoraxjnl-2014-206345-15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/15412550902724073","article-title":"Formoterol and tiotropium compared with tiotropium alone for treatment of COPD","volume":"6","author":"Tashkin","year":"2009","journal-title":"COPD"},{"key":"key-10.1136\/thoraxjnl-2014-206345-16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4104\/pcrj.2011.00102","article-title":"Beyond lung function in COPD management: effectiveness of LABA\/LAMA combination therapy on patient-centred outcomes","volume":"21","author":"van der Molen","year":"2012","journal-title":"Prim Care Respir J"},{"key":"key-10.1136\/thoraxjnl-2014-206345-17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1440-1843.2010.01912.x","article-title":"Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis","volume":"16","author":"Wang","year":"2011","journal-title":"Respirology"},{"key":"key-10.1136\/thoraxjnl-2014-206345-18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/COPD.S49615","article-title":"Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study","volume":"8","author":"Dahl","year":"2013","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"key-10.1136\/thoraxjnl-2014-206345-19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"key-10.1136\/thoraxjnl-2014-206345-20","first-page":"CD008989","article-title":"Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease","volume":"4","author":"Karner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.1136\/thoraxjnl-2014-206345-21","first-page":"CD009285","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","volume":"7","author":"Karner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.1136\/thoraxjnl-2014-206345-22","first-page":"CD010177","article-title":"Long-acting beta2-agonists for chronic obstructive pulmonary disease","volume":"10","author":"Kew","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.1136\/thoraxjnl-2014-206345-23","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"key-10.1136\/thoraxjnl-2014-206345-24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2014-206345-25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"Jones","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.1136\/thoraxjnl-2014-206345-26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","article-title":"Minimal important difference of the transition dyspnoea index in a multinational clinical trial","volume":"21","author":"Witek","year":"2003","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2014-206345-27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1465-9921-11-79","article-title":"Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations","volume":"11","author":"Glaab","year":"2010","journal-title":"Respir Res"},{"issue":"(Suppl 2)","key":"key-10.1136\/thoraxjnl-2014-206345-28","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1111\/j.1524-4733.2009.00557.x","article-title":"Health technology assessment in health-care decisions in the United States","volume":"12","author":"Sullivan","year":"2009","journal-title":"Value Health"},{"key":"key-10.1136\/thoraxjnl-2014-206345-29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1183\/09031936.00124013","article-title":"Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study","volume":"43","author":"Mahler","year":"2014","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2014-206345-30","first-page":"A2257","article-title":"Effects of indacaterol on lung volumes and physical activity in moderate chronic obstructive pulmonary disease","volume":"185","author":"Watz","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.1136\/thoraxjnl-2014-206345-31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1465-9921-12-40","article-title":"Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review","volume":"12","author":"Westwood","year":"2011","journal-title":"Respir Res"},{"key":"key-10.1136\/thoraxjnl-2014-206345-32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","article-title":"Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD","volume":"65","author":"Dahl","year":"2010","journal-title":"Thorax"},{"key":"key-10.1136\/thoraxjnl-2014-206345-33","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1034\/j.1399-3003.1999.13d25.x","article-title":"Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease","volume":"13","author":"Donaldson","year":"1999","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2014-206345-34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1465-9921-14-116","article-title":"Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial","volume":"14","author":"Beeh","year":"2013","journal-title":"Respir Res"},{"key":"key-10.1136\/thoraxjnl-2014-206345-35","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1183\/09031936.04.00121404","article-title":"Impact of preventing exacerbations on deterioration of health status in COPD","volume":"23","author":"Spencer","year":"2004","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2014-206345-36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2014-206345-37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium","volume":"19","author":"Vincken","year":"2002","journal-title":"Eur Respir J"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2014-206345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T05:50:11Z","timestamp":1601099411000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2014-206345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,12]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,3,12]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206345","relation":{},"ISSN":["0040-6376"],"issn-type":[{"value":"0040-6376","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2,12]]}}}